Scoop: ExeVir hits pause on llama-derived Covid antibody amid Omicron variants, shifts focus to second-gen work
ExeVir has returned to the drawing board after pausing work on its first-generation llama-derived Covid-19 antibody and is turning its R&D focus toward a preclinical second-gen attempt, Endpoints News has learned.
The Belgian biotech terminated a study of the antibody, dubbed XVR011, last month due to “change in company strategy for phase 2 design,” according to an update on clinicaltrials.gov. The biotech still awaits some data to confirm the scope of Omicron and its subvariants’ effect on the antibody, but ExeVir is likely to move forward without its first shot at treating the pandemic disease, CEO Torsten Mummenbrauer told Endpoints.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.